Exciting New Data in Newly Diagnosed Multiple Myeloma

Exciting New Data in Newly Diagnosed Multiple Myeloma

Saved in:

Bibliographic Details
Main Author:	Kaveh Samii
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2022-10-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/HBT.OH.2022.13.080
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predicting survival of persons with newly-diagnosed multiple myeloma
by: Limei Zhang, et al.
Published: (2025-08-01)

Outcomes for unselected, newly diagnosed multiple myeloma patients
by: Jonathan T. Moore, et al.
Published: (2025-06-01)

Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
by: Grace M. Ferri, et al.
Published: (2025-01-01)

A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs
by: Ye Li, et al.
Published: (2024-10-01)

Assessment and Treatment of Elderly Patients with Multiple Myeloma
by: Carmen de Ramon Ortiz, et al.
Published: (2024-06-01)

Prognostic value of peripheral eosinophil counts in patients with newly diagnosed multiple myeloma
by: Xu Chen, et al.
Published: (2025-05-01)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
by: Roberto Ria, et al.
Published: (2012-01-01)

Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
by: Wen‐Ying Lin, et al.
Published: (2023-02-01)

IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma
by: Shuaishuai Xu, et al.
Published: (2024-12-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Advancements in the Treatment of High-Risk Smoldering Myeloma: News from ASH 2024
by: Kaveh Samii
Published: (2024-12-01)

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01)

MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: Francesca Fazio, et al.
Published: (2023-08-01)

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
by: Matthew J. Pianko, et al.
Published: (2025-12-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
by: Yuxin Liu, et al.
Published: (2024-10-01)

Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients
by: Xu Si, et al.
Published: (2025-05-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Tregs at Diagnosis as a Potential Biomarker for Predicting High‐Risk Functionality in Newly Diagnosed Multiple Myeloma
by: Qiaolin Zhou, et al.
Published: (2025-06-01)

Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial
by: Lisa B. Leypoldt, et al.
Published: (2025-07-01)

Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Lessons for Resource-Challenged Regions
by: Deepesh P. Lad
Published: (2024-04-01)

Clinical Characteristics and Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients in China
by: Geng C, et al.
Published: (2025-05-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma
by: Christian Brieghel, et al.
Published: (2025-04-01)

Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study
by: Xinhe Shan, et al.
Published: (2025-05-01)

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01)

Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma
by: Chen Hong, et al.
Published: (2025-01-01)

The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma
by: Ruiqi Wang, et al.
Published: (2025-08-01)

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients
by: Linlin Huang, et al.
Published: (2024-12-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

A Randomized Controlled ‘REAL‐FITNESS’ Trial to Evaluate Physical Activity in Patients With Newly Diagnosed Multiple Myeloma
by: Esther Dreyling, et al.
Published: (2025-04-01)

Analysis of coagulation alteration and its correlation with β2-microglobulin in 371 patients with newly diagnosed multiple myeloma
by: Miao Hu, et al.
Published: (2024-12-01)

The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients
by: Shohei Mizuno, et al.
Published: (2025-07-01)

Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Olga Lytvynova, et al.
Published: (2024-09-01)

Genetic and Epigenetic Aberrations of <i>SOX7</i> in Newly Diagnosed and Relapsed Multiple Myeloma as Well as Related Neoplasms
by: Can Küçük, et al.
Published: (2025-04-01)

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma
by: Wenjiao Tang, et al.
Published: (2023-02-01)

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study
by: Dong Liang, et al.
Published: (2025-12-01)

Clinical pathway for diagnosis and treatment of new diagnosed multiple myeloma in Guangxi
by: The Control Center of Medical Quality of Guangxi Hematology, et al.
Published: (2025-04-01)

The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis
by: Huixing Zhou, et al.
Published: (2025-05-01)

Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy
by: Susan Bal, et al.
Published: (2025-04-01)